Sign in

CIK 0002023658 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Bicara Therapeutics Inc.

Sign in to watch
Ticker
BCAX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
617-468-4219
Business address
116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116
  1. 4 Planned sale Chief Financial Officer sold 9,200 shares at $20.42 ($187,883)
  2. 4 Planned sale Chief Executive Officer sold 15,000 shares at an average $20.04 ($300,579)
  3. 4 Planned sale President and COO sold 12,500 shares at $20.29 ($253,649)
  4. 4 Derivatives Options or other derivatives
  5. 3 Insider Initial Statement of Ownership
  6. 4 Planned sale Chief Medical Officer sold 5,500 shares at $22.88 ($125,830)
  7. 4 Planned sale Chief Financial Officer sold 9,200 shares at $23.00 ($211,614)
  8. 4 Planned sale Chief Executive Officer sold 15,000 shares at $23.61 ($354,146)
  9. 4 Planned sale President and COO sold 12,500 shares at $23.01 ($287,591)
  10. 4 Planned sale Chief Medical Officer sold 5,500 shares at $18.95 ($104,229)
  11. 4 Planned sale Chief Financial Officer sold 9,200 shares at $18.52 ($170,348)
  12. 4 Planned sale Chief Executive Officer sold 15,000 shares at an average $18.82 ($282,366)
  13. 4 Planned sale President and COO sold 12,500 shares at $19.66 ($245,714)
  14. 4 Planned sale Chief Executive Officer sold 36,766 shares at $19.17 ($704,657)
  15. 4 Planned sale Chief Executive Officer sold 8,234 shares at an average $18.74 ($154,325)
  16. 4 Planned sale President and COO sold 17,392 shares at $18.16 ($315,893)
  17. 4 Planned sale Chief Financial Officer sold 16,518 shares at an average $18.22 ($300,971)
  18. 4 Planned sale Chief Medical Officer sold 16,500 shares at an average $18.52 ($305,610)
  19. 4 Open-market buy Director bought 300,000 shares at $16.00 ($4,800,000)
  20. 4 Planned sale President and COO sold 3,631 shares at $18.04 ($65,501)

Page 2 of 6 · 107 filings